These findings deepen our understanding of the molecular mechanisms of GBM, filling a gap in the regulatory network of the TMED3-ZBTB7A signaling axis, and suggest that targeting the TMED3-ZBTB7A axis could provide a promising strategy for therapeutic intervention. The gene discussed is ZBTB7A; the disease is glioblastoma.